Matches in Wikidata for { <http://www.wikidata.org/entity/Q37621846> ?p ?o ?g. }
- Q37621846 description "article científic" @default.
- Q37621846 description "article scientifique" @default.
- Q37621846 description "articolo scientifico" @default.
- Q37621846 description "artigo científico" @default.
- Q37621846 description "artículu científicu espublizáu en 2014" @default.
- Q37621846 description "bilimsel makale" @default.
- Q37621846 description "scientific article published on 03 January 2014" @default.
- Q37621846 description "vedecký článok" @default.
- Q37621846 description "vetenskaplig artikel" @default.
- Q37621846 description "videnskabelig artikel" @default.
- Q37621846 description "vědecký článek" @default.
- Q37621846 description "wetenschappelijk artikel" @default.
- Q37621846 description "wissenschaftlicher Artikel" @default.
- Q37621846 description "наукова стаття, опублікована в січні 2014" @default.
- Q37621846 description "научни чланак" @default.
- Q37621846 description "مقالة علمية نشرت في 03 يناير 2014" @default.
- Q37621846 name "A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone." @default.
- Q37621846 name "A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone." @default.
- Q37621846 name "A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone." @default.
- Q37621846 type Item @default.
- Q37621846 label "A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone." @default.
- Q37621846 label "A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone." @default.
- Q37621846 label "A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone." @default.
- Q37621846 prefLabel "A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone." @default.
- Q37621846 prefLabel "A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone." @default.
- Q37621846 prefLabel "A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone." @default.
- Q37621846 P1433 Q37621846-92C4D1E3-A84C-4798-B367-69D277D2896D @default.
- Q37621846 P1476 Q37621846-3B2D8CBB-6200-4F99-B38B-1A3DE8043AFE @default.
- Q37621846 P2093 Q37621846-54E0E8DB-01A7-4AFE-B63A-42B48601C682 @default.
- Q37621846 P2093 Q37621846-5814E92A-D070-4E7C-B7BE-0E4DDDEF4AA1 @default.
- Q37621846 P2093 Q37621846-59D877D0-6691-4D47-BCB8-9D52B029A4FA @default.
- Q37621846 P2093 Q37621846-B8675006-3665-418A-B064-BAA12085F659 @default.
- Q37621846 P2093 Q37621846-E8DDD3B4-A4CD-4764-8DD6-C3F6A43AAFD9 @default.
- Q37621846 P2860 Q37621846-00D49B2D-E991-48ED-9A31-420202E816DF @default.
- Q37621846 P2860 Q37621846-019EEA1E-52F8-4362-B8FC-A185562AF4BB @default.
- Q37621846 P2860 Q37621846-02C3CFED-8183-4A47-BA95-C0D25C3A58E3 @default.
- Q37621846 P2860 Q37621846-03137278-7DCA-45C0-B37D-345305F0284C @default.
- Q37621846 P2860 Q37621846-10A5BF15-F7DE-46A8-9792-D153142AA022 @default.
- Q37621846 P2860 Q37621846-10DE7649-4A3D-4405-9565-21D2DB30AAEE @default.
- Q37621846 P2860 Q37621846-177A2AF1-3457-4B12-A8AD-6B99ECDA15C0 @default.
- Q37621846 P2860 Q37621846-21301525-5AA1-43C4-9AE0-16FEB1F8DC55 @default.
- Q37621846 P2860 Q37621846-2525AACA-831D-45EB-B1A3-35AD7045EAEE @default.
- Q37621846 P2860 Q37621846-2B05F52D-03BB-483B-8E95-8A5E6FAA6602 @default.
- Q37621846 P2860 Q37621846-2C823DBA-008B-4001-B0E6-BFD306CB4716 @default.
- Q37621846 P2860 Q37621846-32711A13-E061-4168-929D-7DB57D090C6E @default.
- Q37621846 P2860 Q37621846-3F075453-24E4-4505-BFFB-116ED46B31B9 @default.
- Q37621846 P2860 Q37621846-42CA3309-112F-42B0-B876-2E1F0410983F @default.
- Q37621846 P2860 Q37621846-4EEEC637-58B4-4C30-B2AE-2056F2EEFFE9 @default.
- Q37621846 P2860 Q37621846-51C520FC-28E7-41B3-A25D-F68342B2BB25 @default.
- Q37621846 P2860 Q37621846-5296152E-6DA6-4286-B8A5-798534D750A8 @default.
- Q37621846 P2860 Q37621846-578A7BEB-032B-4E5C-B885-8F0A67ED4A28 @default.
- Q37621846 P2860 Q37621846-63B9DCF7-4189-48C9-A6A7-F13DE4868F29 @default.
- Q37621846 P2860 Q37621846-66B0D1B7-70AB-433B-BF65-8F759F71BC05 @default.
- Q37621846 P2860 Q37621846-6A9FDD67-B76A-44B5-906A-5BDDD4C609B7 @default.
- Q37621846 P2860 Q37621846-6D1C1C76-29EB-4719-9EF1-48031DD11B9F @default.
- Q37621846 P2860 Q37621846-76241C64-7655-4FA0-8A65-2F614578E556 @default.
- Q37621846 P2860 Q37621846-7E85A1D6-B219-49F9-8202-166C532B8395 @default.
- Q37621846 P2860 Q37621846-81503205-A564-49FC-87CC-6B2F16A0F83A @default.
- Q37621846 P2860 Q37621846-88061244-A654-492D-8E6F-08AFC4BAA99E @default.
- Q37621846 P2860 Q37621846-9261959D-8D51-4573-A754-159AA0232E79 @default.
- Q37621846 P2860 Q37621846-94E76FFE-B9C0-4353-9137-AAA6B19A2378 @default.
- Q37621846 P2860 Q37621846-9B308988-64EA-4DFF-92F1-ABF64954C15B @default.
- Q37621846 P2860 Q37621846-A649B701-C20F-41CD-849B-ADF4AD7316EB @default.
- Q37621846 P2860 Q37621846-C036FE52-4EDC-4E7B-91C0-9B894D773A9D @default.
- Q37621846 P2860 Q37621846-C7C7DF3B-BBD1-44D9-9D94-0F43306AACE6 @default.
- Q37621846 P2860 Q37621846-CEE4DE85-DAFD-452A-BB33-436FA7F817A0 @default.
- Q37621846 P2860 Q37621846-E30716C3-F391-4286-B6DC-AB2C2A0175BF @default.
- Q37621846 P2860 Q37621846-E466986D-986F-49FC-B240-E973C1D47A6C @default.
- Q37621846 P2860 Q37621846-E9321600-114F-4502-8147-7233802AA4A2 @default.
- Q37621846 P2860 Q37621846-EA38CF11-1901-4E09-B539-A6DA745CE423 @default.
- Q37621846 P2860 Q37621846-EA705BDB-8100-48FA-8D9C-41F59D602934 @default.
- Q37621846 P2860 Q37621846-F0437139-8339-4CAF-9530-305328DA95AE @default.
- Q37621846 P2860 Q37621846-FD91C759-E544-4654-8AFB-D8F70AC052EF @default.
- Q37621846 P304 Q37621846-72494480-5EE7-40DD-B455-6695B28C2AF3 @default.
- Q37621846 P31 Q37621846-9DC09F47-EB10-45F7-B08D-A298C44C4AD0 @default.
- Q37621846 P356 Q37621846-32B2679B-D6E5-4100-8378-6A9C5982B3A0 @default.
- Q37621846 P478 Q37621846-02263C53-BB85-41F3-B8FE-036100829934 @default.
- Q37621846 P50 Q37621846-D8B77F02-663E-494C-9625-1D12D831D598 @default.
- Q37621846 P50 Q37621846-E3804E07-51EF-408D-A02C-FDF0F3175188 @default.
- Q37621846 P577 Q37621846-834C73B2-94A5-477C-A09D-1E3884AC4D44 @default.
- Q37621846 P5875 Q37621846-22BBDF0E-C370-471C-9431-32EEE9D12C48 @default.
- Q37621846 P698 Q37621846-23D4673F-827C-4AE0-90F4-DAAD6CCDD74A @default.
- Q37621846 P921 Q37621846-6832C956-A98D-40E1-BA98-0E5E1B7483F1 @default.
- Q37621846 P921 Q37621846-7CF2C976-DA78-4166-A80C-6E3315E33351 @default.
- Q37621846 P921 Q37621846-AEBBD50C-FEF9-4AD8-BE18-0EFBE35CB5AD @default.
- Q37621846 P921 Q37621846-FD9DF8F4-D8E8-451C-8531-E7AA61E14162 @default.
- Q37621846 P932 Q37621846-B5913380-FD34-4079-8ACA-A3E5BC03540D @default.
- Q37621846 P356 J.DRUGALCDEP.2013.12.015 @default.
- Q37621846 P698 24424425 @default.
- Q37621846 P1433 Q5308875 @default.
- Q37621846 P1476 "A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone" @default.
- Q37621846 P2093 "Angela L Stotts" @default.
- Q37621846 P2093 "Charles E Green" @default.
- Q37621846 P2093 "F Gerard Moeller" @default.
- Q37621846 P2093 "Jan A Lindsay" @default.
- Q37621846 P2093 "John Grabowski" @default.
- Q37621846 P2860 Q24652419 @default.
- Q37621846 P2860 Q32055859 @default.
- Q37621846 P2860 Q33572392 @default.
- Q37621846 P2860 Q33909103 @default.